Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice

CX3CR1 is a chemokine receptor expressed on microglia that binds Fractalkine (CX3CL1) and regulates microglial recruitment to sites of neuroinflammation. Full deletion of CX3CR1 in mouse models of Alzheimer's disease have opposing effects on amyloid-β and tau pathologies raising concerns about...

Full description

Bibliographic Details
Main Authors: Suzanne E. Hickman, Elizabeth K. Allison, Uwanda Coleman, Nathan D. Kingery-Gallagher, Joseph El Khoury
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.02780/full
id doaj-6d6b4e7d47734542b0ce925904ccc209
record_format Article
spelling doaj-6d6b4e7d47734542b0ce925904ccc2092020-11-25T00:57:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-12-011010.3389/fimmu.2019.02780498281Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP MiceSuzanne E. Hickman0Elizabeth K. Allison1Uwanda Coleman2Nathan D. Kingery-Gallagher3Joseph El Khoury4Joseph El Khoury5Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United StatesCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United StatesCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United StatesCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United StatesCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United StatesDivision of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United StatesCX3CR1 is a chemokine receptor expressed on microglia that binds Fractalkine (CX3CL1) and regulates microglial recruitment to sites of neuroinflammation. Full deletion of CX3CR1 in mouse models of Alzheimer's disease have opposing effects on amyloid-β and tau pathologies raising concerns about the benefits of targeting CX3CR1 for treatment of this disease. Since most therapies achieve only partial blockade of their targets, we investigated the effects of partial CX3CR1 deficiency on the development and progression of amyloid-β deposition in the PS1-APP Alzheimer's mouse model. We generated PS1-APP mice heterozygous for CX3CR1 (PS1-APP-CX3CR1+/−) and analyzed these mice for Alzheimer's-like pathology. We found that partial CX3CR1 deficiency was associated with a significant reduction in Aβ levels and in senile-like plaque load in the brain as compared with age-matched PS1-APP mice. Reduced Aβ level in the brain was associated with improved cognitive function. Levels of the neuronal-expressed Aβ-degrading enzymes insulysin and matrix metalloproteinase 9, which are reduced in the brains of regular PS1-APP mice, were significantly higher in PS1-APP-CX3CR1+/− mice. Our data indicate that lowering CX3CR1 levels or partially inhibiting its activity in the brain may be a therapeutic strategy to increase neuronal Aβ clearance, reduce Aβ levels and delay progression of Alzheimer's-Like disease. Our findings also suggest a novel pathway where microglial CX3CR1 can regulates gene expression in neurons.https://www.frontiersin.org/article/10.3389/fimmu.2019.02780/fullmicrogliaAlzheimer's diseaseCX3CR1Aβ-degrading enzymesfractalkinechemokines
collection DOAJ
language English
format Article
sources DOAJ
author Suzanne E. Hickman
Elizabeth K. Allison
Uwanda Coleman
Nathan D. Kingery-Gallagher
Joseph El Khoury
Joseph El Khoury
spellingShingle Suzanne E. Hickman
Elizabeth K. Allison
Uwanda Coleman
Nathan D. Kingery-Gallagher
Joseph El Khoury
Joseph El Khoury
Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
Frontiers in Immunology
microglia
Alzheimer's disease
CX3CR1
Aβ-degrading enzymes
fractalkine
chemokines
author_facet Suzanne E. Hickman
Elizabeth K. Allison
Uwanda Coleman
Nathan D. Kingery-Gallagher
Joseph El Khoury
Joseph El Khoury
author_sort Suzanne E. Hickman
title Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
title_short Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
title_full Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
title_fullStr Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
title_full_unstemmed Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
title_sort heterozygous cx3cr1 deficiency in microglia restores neuronal β-amyloid clearance pathways and slows progression of alzheimer's like-disease in ps1-app mice
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2019-12-01
description CX3CR1 is a chemokine receptor expressed on microglia that binds Fractalkine (CX3CL1) and regulates microglial recruitment to sites of neuroinflammation. Full deletion of CX3CR1 in mouse models of Alzheimer's disease have opposing effects on amyloid-β and tau pathologies raising concerns about the benefits of targeting CX3CR1 for treatment of this disease. Since most therapies achieve only partial blockade of their targets, we investigated the effects of partial CX3CR1 deficiency on the development and progression of amyloid-β deposition in the PS1-APP Alzheimer's mouse model. We generated PS1-APP mice heterozygous for CX3CR1 (PS1-APP-CX3CR1+/−) and analyzed these mice for Alzheimer's-like pathology. We found that partial CX3CR1 deficiency was associated with a significant reduction in Aβ levels and in senile-like plaque load in the brain as compared with age-matched PS1-APP mice. Reduced Aβ level in the brain was associated with improved cognitive function. Levels of the neuronal-expressed Aβ-degrading enzymes insulysin and matrix metalloproteinase 9, which are reduced in the brains of regular PS1-APP mice, were significantly higher in PS1-APP-CX3CR1+/− mice. Our data indicate that lowering CX3CR1 levels or partially inhibiting its activity in the brain may be a therapeutic strategy to increase neuronal Aβ clearance, reduce Aβ levels and delay progression of Alzheimer's-Like disease. Our findings also suggest a novel pathway where microglial CX3CR1 can regulates gene expression in neurons.
topic microglia
Alzheimer's disease
CX3CR1
Aβ-degrading enzymes
fractalkine
chemokines
url https://www.frontiersin.org/article/10.3389/fimmu.2019.02780/full
work_keys_str_mv AT suzanneehickman heterozygouscx3cr1deficiencyinmicrogliarestoresneuronalbamyloidclearancepathwaysandslowsprogressionofalzheimerslikediseaseinps1appmice
AT elizabethkallison heterozygouscx3cr1deficiencyinmicrogliarestoresneuronalbamyloidclearancepathwaysandslowsprogressionofalzheimerslikediseaseinps1appmice
AT uwandacoleman heterozygouscx3cr1deficiencyinmicrogliarestoresneuronalbamyloidclearancepathwaysandslowsprogressionofalzheimerslikediseaseinps1appmice
AT nathandkingerygallagher heterozygouscx3cr1deficiencyinmicrogliarestoresneuronalbamyloidclearancepathwaysandslowsprogressionofalzheimerslikediseaseinps1appmice
AT josephelkhoury heterozygouscx3cr1deficiencyinmicrogliarestoresneuronalbamyloidclearancepathwaysandslowsprogressionofalzheimerslikediseaseinps1appmice
AT josephelkhoury heterozygouscx3cr1deficiencyinmicrogliarestoresneuronalbamyloidclearancepathwaysandslowsprogressionofalzheimerslikediseaseinps1appmice
_version_ 1725224116031586304